颈外动脉栓塞用顺铂白蛋白微球的研究

用乳化化学交联法制备出适合于颌面部鳞癌殒外动脉栓塞用顺铂白蛋白微球;外观呈黄色粉末状,收率80±5%,显微观察呈圆球体,平场粒径56.3μm:药物含量为14.02～14.2%,包封率97.08～97.95%。对其体外释药、灭菌、稳定性及分散溶媒的处方进行了探讨。通过动物实验表明该微球可以达到理想的栓塞效果,并保证能在局部组织停留,有利于提高抗癌药物的疗效,降低毒副作用。     

苦绳的甾体成分

从苦绳(Dregea sinensis Hemsl.)中分离到两个新化合物∶苦绳甙元乙(dresigeninB,1)和苦绳甙I(dresiosideI,2)。经光谱和化学反应确定其结构为∶20-O-(2-甲基丁酰基) 托曼托甙元[20-O-(2-methylbutyryl)-tomentogenin]和二氢肉珊瑚甙元3-O-β-D-吡喃黄夹糖基(1-4)-β-D-吡喃夹竹桃糖基(1-4)-β-D-吡喃磁麻糖甙[dihydrosarcostin 3-O-β-D-thevetopyranosyl(1-4)-β-D-oleandropyranosyl(1-4)-β-D-cymaropyranoside]。     

心肌缺血再灌注损伤与热休克蛋白

目的:热休克蛋白是细胞在应激条件下产生的一类高度保守的蛋白质,它可以从抵抗损伤和加速修复两个方面对细胞进行保护。研究表明热休克蛋白对心肌缺血再灌注损伤有内源性的抵抗作用。本文对热休克蛋白及其内源性抵抗心肌缺血再灌注损伤的作用机制进行综述。资料来源:①从图书馆手工查阅相关领域的学术期刊,重点是核心期刊,查阅有关心肌损伤与热休克蛋白之间关系的文献,关键词为“心肌损伤、热休克蛋白、缺血再灌注”。②在cnki数据库及PubMed检索2000/2006心肌缺血再灌注损伤保护方面的文献资料,关键词是“心肌损伤、热休克蛋白”。资料选择:手工和应用计算机分别检索到13篇和29篇与热休克蛋白与心肌缺血再灌注损伤有关的文献。纳入标准:选择实验性文献,即一次性文献。对于内容相近的文献选择在核心期刊发表或年限较近的文章。排除标准:重复性研究。资料提炼:共得到35篇文献,其中2004/2006的文献有14篇,2000/2003的文献7篇。资料综合:热休克蛋白是细胞在应激情况下启动热休克基因从而产生的一种结构高度保守的蛋白质,几乎存在于从原核生物到真核生物的所有生物体。它具有非特异性、高度保守性、热休克蛋白70表达突出性、时间性、弱的ATP酶的活性和交叉耐受性等特性。热休克蛋白对细胞具有保护作用,主要表现在抵抗损伤和加速修复这两方面。20世纪80年代末,人们开始注意到热休克蛋白具有心肌保护作用,1988年,Currie等将SD大鼠进行热休克预处理,待其恢复24h后,进行离体心肌缺血再灌注,结果发现热休克组大鼠心肌缺血再灌注损伤后力学指标的恢复明显改善,心肌超微结构的损伤也有不同程度的减轻。热休克蛋白抵抗心肌缺血再灌注损伤的机制包括:稳定细胞内变性的蛋白质;减轻细胞内的离子紊乱;保护血管内皮细胞的功能;干扰应激所启动的细胞调亡程序等4个方面。结论:热休克蛋白对心肌缺血再灌注损伤具有内源性的抵抗作用。     

纳米羟基磷灰石沉积层/钛酸钾薄层/钛合金生物复合材料体外培养成骨细胞的研究

在制备出具有表面活性的纳米羟基磷灰石沉积层/钛酸钾薄层/钛合金（HA/K2Ti6O13/β-Ti）生物复合材料的基础上,将体外培养的成骨细胞与HA/K2Ti6O13/β-Ti生物复合材料、未经处理β钛合金两种骨替代材料共同培养,在既定时间内观察两种骨替代材料对成骨细胞生长、附着的影响。结果表明两种骨替代材料对成骨细胞生长无明显抑制或促进作用,均具有良好的细胞相容性,它们皆能使成骨细胞附着于各自材料表面,分泌形成胶原纤维样基质。HA/K2Ti6O13/β-Ti生物复合材料较β钛合金具有更优异的的生物活性和成骨性能,是一种很好的生物植入材料。     

1-(α-萘甲基)-2甲基-6,7-二甲氧基-1,2,3,4-四氢异喹啉盐酸盐的HPLC手性拆分法及半制备

1-(α-Naphthylmethy)-2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolinehydrochloride (code No, 86040)is a new kind of calcium antagonist. It has(+)and(一)enantiomers.Accordingly .the resolution and quantification of these two enantiomers have received agreat deal of attention,In this report the application of direct HPLC separation and semipreparation tothe determination of the enantiomeric composition of the new drug are described. All analysis andsemipreparation were performed with 25 cm×4. 6 mm i.d, 25 cm×8 mm i,d.and 30 cm×8 mmi.d. stainless steel column packed with a chiral β-cycledextrin bonded phase. Detection wavelengthwas 284 nm, The optimal composition of the mobile phase was EtOH─pH 4.0 phosphate buffer(35:65) at flow rate of 0. 3 ml·min^-1 for analysis and l.0 ml·min^-1 for semipreparation. Theseparation factor of the enantiomers was l.25. Purity of the semipreparation was 8l.4%,Quantityof semipreparation was 1 mg. This procedure was simple ,rapid and gave good resolution,The effectsof the composition of mobile phase, pH value, flow rate and column temperature on the resolution hadbeen sudied.     

The DSM Diagnostic Criteria for Dyspareunia

The DSM-IV-TR attempted to create a unitary category of dyspareunia based on the criterion of genital pain that interfered with sexual intercourse. This classificatory emphasis of interference with intercourse is reviewed and evaluated from both theoretical and empirical points of view. Neither of these points of view was found to support the notion of dyspareunia as a unitary disorder or its inclusion in the DSM-V as a sexual dysfunction. It seems highly likely that there are different syndromes of dyspareunia and that what is currently termed “superficial dyspareunia” cannot be differentiated reliably from vaginismus. It is proposed that the diagnoses of vaginismus and dyspareunia be collapsed into a single diagnostic entity called genito-pelvic pain/penetration disorder. This diagnostic category is defined according to five dimensions: percentage success of vaginal penetration; pain with vaginal penetration; fear of vaginal penetration or of genito-pelvic pain during vaginal penetration; pelvic floor muscle dysfunction; medical co-morbidity.     

Efficacy of a 1‐week rabeprazole triple therapy for eradicating Helicobacter pylori and ulcer healing: an ‘in‐clinical‐practice’ study

OBJECTIVE: To determine the efficacy and tolerability of a 1‐week treatment regimen consisting of rabeprazole and two antibiotics, clarithromycin and amoxicillin, in the eradication of Helicobacter pylori in an ‘in‐clinical‐practice’ setting. METHODS: Patients selected had unequivocal evidence of H. pylori infection based on urease test and histology of antral and corpus biopsies obtained at endoscopy. Patients with complicated ulcers were not included. Patients received rabeprazole 10 mg b.i.d., clarithromycin 500 mg b.i.d. and amoxicillin 1 g b.i.d. for 1 week and were assessed for successful eradication at least 4 weeks after completion of therapy by repeat gastroscopy and gastric biopsies. Eradication was defined as absence of bacteria in both antral and corpus biopsies tested by histology and urease test. Ulcer patients did not receive continued acid suppression therapy following the 1‐week course of treatment. RESULTS: The study recruited 205 patients of whom 25 were not compliant with the medications or defaulted on follow‐up and were therefore not included in the per‐protocol analysis. Eradication of H. pylori was successful in 166/180 of patients on per‐protocol analysis (92.2% [95% CI: 87.3, 95.7]) and in 169/205 patients on intention‐to‐treat analysis (82.4% [95% CI: 80.5, 90.2]; P = 1.000). There were 47 patients with active ulcers: DU 27, GU 18, DU/GU 2. Overall, ulcer healing was achieved in 42 of 44 (95.5%) patients who had successful eradication of H. pylori infection, but ulcers did not heal in any of the three patients (DU 2, GU 1) who did not eradicate the infection. Of the total group, 199 were assessed for compliance and side‐effects of treatment. Side‐effects were in general mild and tolerable. Of 14 patients who were not compliant with medication, 4 (2.0%) attributed it to side‐effects of treatment (increased abdominal pain, dizziness and taste disturbances) and the remaining 10 did not give specific reasons. The most common side‐effect was bitter taste, reported by 39.2% of patients. Other side‐effects, such as giddiness, increased abdominal pain, lethargy, loose bowel motions and skin rash, were mild and found in only a small percentage of patients. CONCLUSIONS: The rabeprazole 1‐week triple therapy with amoxicillin and clarithromycin is effective in eradicating H. pylori in an ‘in‐clinical‐practice’ setting. The treatment was well tolerated by patients. Good ulcer healing was achieved with short‐course H. pylori eradication therapy without the need for continued acid suppression.